Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT05894447 |
Title | Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers |
Recruitment | Withdrawn |
Gender | both |
Phase | Phase I |
Variant Requirements | No |
Sponsors | Weill Medical College of Cornell University |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA |